Updates in the Management of Clostridium Difficile for Adults

Kimberly E. Ng, PharmD, BCPS


US Pharmacist. 2019;44(4):HS9-HS12. 

In This Article


Rifaximin inhibits bacterial RNA synthesis by binding to bacterial DNA-dependent RNA polymerase. Rifaximin is recommended in the guidelines as an adjunctive post-vancomycin treatment regimen for patients with recurrent CDI. It is not absorbed and therefore has minimal systemic effects, but there are concerns regarding potential resistance with rifaximin use. Reported common side effects include dizziness, fatigue, and nausea.[4,6,10]